{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:32:45Z","timestamp":1791027165410,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.05.012","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T11:39:14Z","timestamp":1717673954000},"page":"1267-1279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-3465","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.05.012_b0005","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.012_b0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.012_b0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.acuro.2023.01.004","article-title":"BCG unresponsive non-muscle invasive bladder cancer: the beginning of a new era?","volume":"47","author":"Guerrero-Ramos","year":"2023","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2024.05.012_b0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non\u2013muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0045","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.euo.2024.05.012_b0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.euo.2024.05.012_b0055","article-title":"PIVOT-006: a phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT)","volume":"42","author":"Svatek","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0070","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.05.012_b0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2024.05.012_b0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2023.41.6_suppl.504","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non\u2013muscle-invasive bladder cancer (IR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: Cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2024.05.012_b0085","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0090","first-page":"574","article-title":"New immunotherapies for high-risk non-muscle invasive bladder cancer: current state and future perspectives","volume":"44","author":"Gomez Del Canizo","year":"2020","journal-title":"Actas Urol Esp"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2024.05.012_b0095","doi-asserted-by":"crossref","first-page":"S1701","DOI":"10.1016\/S0302-2838(24)01302-2","article-title":"First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Gu\u00e9rin (BCG) upfront combination in BCG-na\u00efve high risk non-muscle invasive bladder cancer patients","volume":"85","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/fon-2023-0271","article-title":"CREST: phase III study of sasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer","volume":"20","author":"Steinberg","year":"2024","journal-title":"Future Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2024.05.012_b0105","article-title":"Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus bacillus Calmette-Gu\u00e9rin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B","volume":"40","author":"Kamat","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2024.05.012_b0110","article-title":"A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)","volume":"37","author":"De Santis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2024.05.012_b0120","doi-asserted-by":"crossref","first-page":"S1224","DOI":"10.1016\/j.annonc.2023.09.2825","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Gu\u00e9rin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2024.05.012_b0125","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.111","article-title":"LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0130","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naive high-grade non\u2013muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2024.05.012_b0140","article-title":"Phase 1a\/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1)","volume":"40","author":"Bandari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2024.05.012_b0145","article-title":"Phase 1b\/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer","volume":"41","author":"Sun","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0155","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0170","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"Electromotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.05.012_b0175","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0180","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0185","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semradonc.2022.10.003","article-title":"Pushing the envelope: the role of radiation therapy in non-muscle-invasive bladder cancer","volume":"33","author":"Kombathula","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2024.05.012_b0195","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0205","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/imt-2019-0083","article-title":"Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guerin unresponsive bladder cancer","volume":"11","author":"Shariat","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.euo.2024.05.012_b0210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille Calmette-Gu\u00e9rin in patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.euo.2024.05.012_b0225","doi-asserted-by":"crossref","first-page":"11.e9","DOI":"10.1016\/j.urolonc.2021.07.007","article-title":"Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: results of a prospective European multicentre study at 15 months from treatment start","volume":"40","author":"Hurle","year":"2022","journal-title":"Urol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2024.05.012_b0230","doi-asserted-by":"crossref","first-page":"S1492","DOI":"10.1016\/S0302-2838(24)01158-8","article-title":"Efficacy of intravesical nadofaragene firadenovec-vncg for patients with bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial","volume":"85","author":"Boorjian","year":"2024","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2024.05.012_b0235","first-page":"e408","article-title":"PD13-08 Core1: phase 2 single arm study of CG0070 Combined with pembrolizumab in patients with non muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (BCG)","volume":"209","author":"Li","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.05.012_b0240","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2024.05.012_b0245","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2024.05.012_b0250","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2023.41.16_suppl.4596","article-title":"A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): interim results of a phase 1 study (EV-104)","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non\u2013muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.05.012_b0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.05.012_b0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euf.2020.05.004","article-title":"Stratification of intermediate-risk non\u2013muscle-invasive bladder cancer patients: implications for adjuvant therapies","volume":"7","author":"Soria","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.05.012_b0270","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.012_b0275","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.acuro.2024.01.008","article-title":"Multidisciplinary consensus document on the current treatment of bacille Calmette-Guerin-unresponsive non-muscle invasive bladder tumor","volume":"48","author":"Guerrero-Ramos","year":"2024","journal-title":"Actas Urol Esp"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:11:32Z","timestamp":1737832292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124001433"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}